VMY-1-103, identified by its CAS number 1209002-43-6, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential applications in pharmacology. While specific characteristics such as molecular weight, structure, and solubility may vary, compounds in this category are often characterized by their unique functional groups and biological activity. VMY-1-103 is typically studied for its interactions with biological targets, which may include enzymes or receptors, influencing various physiological processes. Its efficacy and safety profile are evaluated through preclinical and clinical studies, focusing on its therapeutic potential. Additionally, the compound's stability, reactivity, and compatibility with other substances are crucial for its application in drug formulation. As research progresses, detailed information regarding its mechanism of action, pharmacokinetics, and potential side effects will be essential for understanding its role in therapeutic contexts. Always refer to the latest scientific literature for the most current and comprehensive data regarding this compound.

VMY-1-103

1209002-43-6: VMY-1-103, identified by its CAS number 1209002-43-6, is a chemical compound that has garnered attention in the field of medicinal chemistry, particularly for its potential applications in pharmacology. While specific characteristics such as molecular weight, structure, and solubility may vary, compounds in this category are often characterized by their unique functional groups and biological activity. VMY-1-103 is typically studied for its interactions with biological targets, which may include enzymes or receptors, influencing various physiological processes. Its efficacy and safety profile are evaluated through preclinical and clinical studies, focusing on its therapeutic potential. Additionally, the compound's stability, reactivity, and compatibility with other substances are crucial for its application in drug formulation. As research progresses, detailed information regarding its mechanism of action, pharmacokinetics, and potential side effects will be essential for understanding its role in therapeutic contexts. Always refer to the latest scientific literature for the most current and comprehensive data regarding this compound.

<p>VMY-1-103: a strong CDK inhibitor better than purvalanol B; halts prostate/breast cancer cell growth, induces apoptosis, may treat medulloblastoma.</p>

CAS 1209002-43-6

VMY-1-103

VMY-1-103

Ref: TM-T71230